King Wealth Management Group Has $763,000 Holdings in Stevanato Group S.p.A. (NYSE:STVN)

King Wealth Management Group lessened its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 63.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 35,000 shares of the company’s stock after selling 59,800 shares during the period. King Wealth Management Group’s holdings in Stevanato Group were worth $763,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Van Berkom & Associates Inc. bought a new stake in Stevanato Group during the 4th quarter worth about $39,000. PNC Financial Services Group Inc. raised its holdings in Stevanato Group by 1,457.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock worth $123,000 after acquiring an additional 5,291 shares in the last quarter. US Bancorp DE raised its holdings in Stevanato Group by 17.9% during the fourth quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after acquiring an additional 1,295 shares in the last quarter. Marco Investment Management LLC acquired a new position in Stevanato Group during the fourth quarter valued at approximately $203,000. Finally, Hardy Reed LLC grew its stake in Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after purchasing an additional 840 shares in the last quarter.

Stevanato Group Stock Performance

Shares of STVN stock opened at €19.82 ($21.54) on Friday. Stevanato Group S.p.A. has a 52 week low of €16.56 ($18.00) and a 52 week high of €33.49 ($36.40). The company has a market capitalization of $6.00 billion, a price-to-earnings ratio of 42.17, a PEG ratio of 7.18 and a beta of 0.60. The company has a 50-day simple moving average of €21.30 and a 200 day simple moving average of €20.58. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. On average, sell-side analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on STVN shares. Morgan Stanley reiterated an “equal weight” rating and set a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Bank of America boosted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Wolfe Research began coverage on shares of Stevanato Group in a research note on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price for the company. Finally, UBS Group reduced their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of €27.75 ($30.16).

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.